RBC Capital raised the firm’s price target on Biogen (BIIB) to $219 from $208 and keeps an Outperform rating on the shares after its Q2 earnings beat. The firm is positive on the company’s strong performance from Leqembi and the MS franchise – even allowing for some one-time benefits – along with solid sales across their other programs, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target lowered to $142 from $143 at BofA
- Promising Developments in Biogen’s IgAN Treatments Drive Buy Rating
- Biogen price target raised to $135 from $125 at Citi
- Biogen price target raised to $194 from $187 at H.C. Wainwright
- Cautious Hold on Biogen Amid Modest Growth Prospects and Uncertain Pipeline